Abstract
Although there has been renewed interest in the serotonin (5-HT) system in schizophrenia, direct evidence for 5-HT dysfunction is limited. This study compares the responses of m-chlorophenyl-piperazine (mCPP), a 5-HT agonist, in first-episode schizophrenia and a known psychotogenic dopamine agonist, methylphenidate. Eighteen patients experiencing their first episode of psychosis and eight healthy controls received methylphenidate (0.5 mg/kg) and mCPP (0.1 mg/kg) intravenously. Behavioral assessments were done before and after the procedure, and a peak response to each agent was rated. Methylphenidate, but not mCPP, produced psychotic symptoms in patients. mCPP did decrease anxiety, hallucinations, and anger and increased agitation, somatic concern, and impaired understandability. Both agents had limited effects on controls. In conclusion, unlike methylphenidate, mCPP did not produce psychotic symptom activation in schizophrenic patients in, and its effects appeared to be nonspecific.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koreen, A., Lieberman, J., Alvir, J. et al. The Behavioral Effect of m-Chlorophenylpiperazine (mCPP) and Methylphenidate in First-Episode Schizophrenia and Normal Controls. Neuropsychopharmacol 16, 61–68 (1997). https://doi.org/10.1016/S0893-133X(96)00160-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/S0893-133X(96)00160-1
Keywords
This article is cited by
-
Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?
CNS Drugs (2020)
-
Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders
Molecular Psychiatry (2018)
-
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine
Neuropsychopharmacology (2015)